

PrEP for HIV Prevention

Adherence to PrEP Testing Guidelines in the U.S.

Joanne Stekler, MD MPH

Professor of Medicine, Epidemiology, and Global Health
University of Washington

June 1, 2023

Last Updated: May 31, 2023

Disclosures

Only FTC/TDF (Truvada), FTC/TAF (Descovy), and CAB-LA (Apretude) are approved by the U.S. Food and Drug Administration (FDA) and only for use in some, but not all, populations. This talk may include discussion of non-FDA approved strategies for HIV prevention.

Disclaimer

Funding for this presentation was made possible by U1OHA29296 from the Human Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. *Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.*

Adherence to HIV Pre-Exposure Prophylaxis Testing Guidelines in the United States

- PrEP guidelines exist but little is known about guideline adherence and quality of U.S. PrEP care.
- No data are available as to what factors might be associated with better quality of care (e.g. PCP v ID, # of PrEP patients).
- These associations might identify ways to inform interventions to improve care.

(And I wanted to explore issues related to guideline adherence, the FDA package insert, and the “standard of care.”)

Adherence to HIV Pre-Exposure Prophylaxis Testing Guidelines in the United States

Methods

- Pharmacy-based records
 - Insured individuals
 - Claims for inpatient admissions, outpatient services, and medications
- Patients who started PrEP 2011-2019.
 - Because pharmacy claims do not have provider names, the provider was assigned who made claims related to PrEP care closest to first PrEP prescription, prioritizing PCP/ID doctors and claims prior to PrEP start.
 - All subsequent tests were assigned to that provider.
 - Dichotomized providers as having 1 versus >1 PrEP patient.

Adherence to HIV Pre-Exposure Prophylaxis Testing Guidelines in the United States

Methods

- Tests for PrEP care were identified using broad CPT codes.
- Adherence = HIV test within 7d of PrEP start, 14d of anticipated visit
- “Higher quality” = providers who had claims for >60% of tests.
- Many sensitivity analyses.

US Public Health Service

**PREEXPOSURE PROPHYLAXIS FOR
THE PREVENTION OF HIV
INFECTION IN THE UNITED STATES
– 2021 UPDATE**

A CLINICAL PRACTICE GUIDELINE



Adherence to HIV Pre-Exposure Prophylaxis Testing Guidelines in the United States

Results

- 29,660 patients who started PrEP during study period.
 - 12,083 (41%) were linked to a provider.
- 70% of providers were linked to only one patient.
- 6% of providers met definition of “higher quality.”
 - 32% had no testing claims within the baseline (7d) or follow-up (14d) windows.
 - 40% had no claims for HIV testing within the windows.

“Higher quality” providers were more likely:

PCPs > ID (OR 1.64, 0.93-2.90)

Only 1 PrEP pt (OR 0.42, 0.3-0.59)

Adherence to HIV Pre-Exposure Prophylaxis Testing Guidelines in the United States

Limitations

- Population represents only insured patients, 2011-19.
- Challenges of the database
 - Linking patients and providers
 - Includes only testing that resulted in claims

Adherence to HIV Pre-Exposure Prophylaxis Testing Guidelines in the United States

Conclusions?

- Do providers with only 1 PrEP patient follow guidelines more?
- Do more experienced providers do same day PrEP and don't ensure that testing is completed?
- Are pts of more experienced providers more likely to use insurance for medications but seek free HIV/STI testing?
- This sort of assessment is challenging...

Clinical Practice Guidelines

- Clinical practice guidelines improve patient outcomes.
- Institute of Medicine report to standardize guidelines (1990, updated 2011).
CPCs should be:
 - Based on systemic review of evidence,
 - Be developed by knowledgeable, multidisciplinary panel of experts and representatives from key affected groups,
 - Consider important patient subgroups and preferences, if appropriate,
 - Have an explicit and transparent process to minimize bias and conflicts of interest,
 - Provide ratings of both quality of evidence and strength of recommendations,
 - Be revised as appropriate.

Clinical Practice Guidelines Issues

- CPG development
 - Quality of evidence
 - Bias and conflicts of interest
 - Obsolescence
- CPG implementation
 - Challenges in dissemination
 - Problems if multiple guidelines with conflicting recommendations
 - Desire for physician autonomy
 - Rarely consider rare conditions
 - Guidelines don't allow for individual variation or preference

Clinical Practice Guidelines

Do you have to follow guidelines if evidence is weak?




Figure 1. Comparison of 41 guidelines using percentage distribution of quality of evidence underlying individual recommendations. ART indicates antiretroviral therapy; HIV, human immunodeficiency virus; and OI, opportunistic infection. *Used a grading system that constituted a modification of the standard Infectious Diseases Society of America evidence-grading system.

- 41 IDSA guidelines issued 1994-2010
- 4218 individual recommendations
 - 14% level I (at least 1 RCT)
 - 31% level II
 - 55% level III (expert opinion only)
- Among class A recs (good evidence)
 - 23% based on level I evidence
 - 37% based on level III

This is an old example...

Clinical Practice Guidelines

Should you follow guidelines that are out of date?

2016 HHS Nonoccupational PEP Regimens for Adults and Adolescents

Preferred Regimen

Dolutegravir + Tenofovir DF-Emtricitabine

Raltegravir + Tenofovir DF-Emtricitabine

Alternative Regimen

Darunavir + Ritonavir + Tenofovir DF-Emtricitabine

Regimens for Patients with CrCl <60 ml/min

Replace Tenofovir DF-Emtricitabine with Zidovudine plus Lamivudine*

*Adjust doses for degree of renal impairment

Clinical Practice Guidelines

Do their use impact litigation and malpractice claims?

- “Clinical practice guidelines ... are designed to improve care, not to define standard of care.”
- No set standard whether CPGs can/cannot be used in litigation.


FDA approvals and package inserts

Do you have to follow them?

“The FDA does not regulate the practice of medicine...”

- Do you *have* to follow the package insert?
 - E.g. at least quarterly HIV testing for TDF/FTC (Truvada) for PrEP or HIV NAT for CAB
- Off-label use of FDA-approved medicines is perfectly legal and can represent the standard of care.
- States differ whether the package insert is considered the standard of care.
- FDA does prohibit manufacturers from promoting/supporting off-label use.

Questions?



Acknowledgment

This Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$3,098,654 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.

